Lantern Pharma Inc.
LTRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001763950
No open-market purchases or sales by Lantern Pharma Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $12.0M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Lantern Pharma Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 22 | 25 | +3 |
| Shares | 1.35M | 1.40M | +53.9K (+4.0%) |
| Value | $19.7M | $15.7M | −$4.00M (−20.4%) |
New holders (5)
Institutions that held Lantern Pharma Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Raymond James & Associates | 25,879 | $289.0K | 0.00% |
| State Street Corp | 25,567 | $286.0K | 0.00% |
| Millennium Management LLC | 12,688 | $142.0K | 0.00% |
| Susquehanna International Group, LLP | 10,909 | $122.0K | 0.00% |
| AdvisorNet Financial, Inc | 500 | $6.00K | 0.00% |
Sold out (2)
Institutions that held Lantern Pharma Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| FMR LLC | 1 | $0 |
| Royal Bank of Canada | 13 | $0 |